Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Tagara (Valeriana wallichii) is an Ayurvedic nervine herb containing valerenic acid and isovaleric acid that modulates GABA neurotransmitter activity. This Himalayan valerian species enhances sleep quality and reduces anxiety by inhibiting GABA breakdown and promoting relaxation.
Reported Benefits (Provisional)
Origin & History
Tagara, also known as Valeriana wallichii, is a perennial herb native to the Himalayan regions of India. It is harvested for its roots, which are dried and used in various traditional medicines.
Research Narrative (Provisional)
Research on Tagara includes randomized controlled trials (RCTs) that suggest its efficacy in reducing anxiety and improving sleep quality. However, more studies are needed to fully establish its benefits.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Tagara (Valeriana wallichii) is primarily valued for its bioactive phytochemicals rather than macronutrient content. Macronutrients: Carbohydrates approximately 50-60% of dry weight (primarily structural polysaccharides and starch in rhizomes), Crude protein approximately 8-12% dry weight, Crude fiber approximately 15-20% dry weight, Fats approximately 2-5% dry weight including essential fatty acids. Key Bioactive Compounds: Valerenic acid and its derivatives (acetoxy-valerenic acid, hydroxy-valerenic acid) at approximately 0.3-0.8% of dry rhizome weight — primary sedative and GABA-modulating constituents; Isovaleric acid and isovaleric acid esters approximately 0.5-1.0% contributing to characteristic odor and mild sedative action; Valepotriates (iridoid esters: valtrate, isovaltrate, didrovaltrate) at approximately 0.5-2.0% dry weight in fresh root, highly unstable and degrade upon drying; Alkaloids including actinidine, chatinine, and valeranine at trace concentrations of approximately 0.01-0.05% dry weight; Flavonoids including linarin and hesperidin at approximately 0.1-0.3%; Sesquiterpenes including kessane, patchouli alcohol derivatives, and valerenal at approximately 0.3-0.7% in volatile oil fraction; Essential oil content 0.3-0.8% of dry weight containing bornyl acetate, beta-caryophyllene, and valeranone. Minerals: Calcium approximately 800-1200 mg/100g dry weight, Potassium approximately 600-900 mg/100g dry weight, Magnesium approximately 150-250 mg/100g dry weight, Iron approximately 10-20 mg/100g dry weight, Zinc approximately 2-5 mg/100g dry weight. Vitamins: Limited data available; small amounts of B-complex vitamins including niacin approximately 1-3 mg/100g and riboflavin approximately 0.1-0.3 mg/100g reported. Bioavailability Notes: Valerenic acid demonstrates moderate oral bioavailability with hepatic first-pass metabolism; valepotriates are poorly bioavailable orally due to instability in aqueous and acidic conditions but may act locally in the GI tract; lipophilic sesquiterpenes show enhanced absorption when consumed with dietary fats; aqueous extracts retain flavonoids and some alkaloids but lose volatile sesquiterpenes, while ethanolic extracts better preserve valerenic acid and valepotriates.
Reported Mechanism (Provisional)
Tagara's primary bioactive compounds valerenic acid and isovaleric acid enhance GABAergic neurotransmission by inhibiting GABA transaminase enzyme and increasing GABA receptor binding affinity. The herb also modulates adenosine A1 receptors to promote sedation and increases cerebral blood flow through vasodilation. These mechanisms collectively reduce neural excitability and promote relaxation responses in the central nervous system.
Clinical Narrative (Provisional)
Clinical studies on Tagara show promising results with small to moderate sample sizes typically ranging from 30-100 participants. Sleep quality studies demonstrate 25-30% improvements in sleep efficiency and reduced sleep onset time within 2-4 weeks of supplementation at 300-600mg daily doses. Anxiety reduction trials report 20-40% decreases in anxiety scores using standardized assessment tools, though most studies are short-term lasting 4-8 weeks. Evidence quality is moderate with most research consisting of randomized controlled trials, though larger long-term studies are needed to confirm sustained benefits.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.